Innate Pharma nine-month revenue rises to €3.4M

The update includes an anticipated cash horizon through the end of Q1 2028 and clinical and regulatory milestones expected or planned during 2027.

Available on EDGAR 11/05/2026 - 06:21 AM EST Accepted by SEC EDGAR 11/05/2026 - 06:20 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Innate Pharma SA reported its third-quarter 2026 business and financial update. Cash, cash equivalents and financial assets were €96.8 million as of September 30, 2026, and financial liabilities were €16.2 million on that date. The company anticipates a cash horizon until the end of Q1 2028. Revenue for the first nine months of 2026 was €3.4 million, compared with €2.3 million in the same period of 2025. The cash figure includes the $75 million Sobi upfront payment and aggregate gross proceeds from the €30 million ordinary-share private placement in August 2026.

IPH4502 Phase 1 dose-escalation enrollment is complete, with 76 patients enrolled; data are scheduled for presentation November 18, 2026. First patient dosing in lacutamab’s Phase 3 TELLOMAK-3 is expected in Q1 2027; an FDA accelerated approval filing in Sézary syndrome is planned for H2 2027 once TELLOMAK-3 is underway. The AstraZeneca-led PACIFIC-9 readout is expected in the first half of 2027, revised from the second half of 2026 because the study is event-driven. Chief Financial Officer Frédéric Lombard will step down December 31, 2026, and Innate has initiated a search for a replacement.

1 point · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointNine-month revenue reached €3.4 million, versus €2.3 million in the same period of 2025.

Negative

• None.

Filing Explained

Remaining capacity of seventy-five million dollars could fund gradual new-share sales, which would increase share count and reduce existing holders’ ownership percentages.

This Form 6-K furnishes Innate Pharma’s quarterly update and incorporates the report and most of its exhibit into existing Form F-3 and Form S-8 registration statements as of November 5, 2026. Innate also reports $75 million remaining under its April 2023 at-the-market agreement; this is capacity for gradual new-share sales at prevailing prices, and using it would increase the share count and reduce existing holders’ percentage ownership absent offsetting changes.

Key Figures

Cash, cash equivalents and financial assets: €96.8 million Financial liabilities: €16.2 million Revenue: €3.4 million +5 more

8 metrics

Cash, cash equivalents and financial assets €96.8 million As of September 30, 2026

Financial liabilities €16.2 million As of September 30, 2026

Revenue €3.4 million First nine months of 2026; €2.3 million for the same period of 2025

Anticipated cash horizon Until the end of Q1 2028 Company estimate

IPH4502 Phase 1 dose-escalation enrollment 76 patients Enrollment complete

At-The-Market balance available $75 million Under the April 2023 sales agreement as of September 30, 2026

Private placement offering €30 million Ordinary shares; occurred in August 2026

Sobi upfront payment $75 million Included in cash, cash equivalents and financial assets as of September 30, 2026

Key Terms

antibody-drug conjugates (ADCs), dose-escalation, accelerated approval, event-driven, +1 more

5 terms

antibody-drug conjugates (ADCs) technical

"proprietary pipeline is centered on antibody-drug conjugates (ADCs)"

Antibody-drug conjugates (ADCs) are advanced medicines that combine a targeted antibody with a powerful drug, acting like a guided missile to deliver treatment directly to cancer cells while sparing healthy tissue. This precision approach can improve effectiveness and reduce side effects, making ADCs a promising area of biotech innovation. For investors, advancements in ADC technology can signal potential growth opportunities in the pharmaceutical and healthcare sectors.

dose-escalation medical

"Phase 1 dose-escalation of the IPH4502-101 study"

Dose-escalation is the part of an early-stage clinical trial where researchers gradually increase a drug’s dose in small groups of participants to find the safest and most effective amount. Think of it like turning up the volume slowly to find the sweet spot: investors watch these results closely because they reveal safety risks, potential effectiveness, and how quickly a drug can move to later trials or approval, all of which affect the development timeline and commercial prospects.

accelerated approval regulatory

"plans an FDA filing in H2 2027 for accelerated approval"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

event-driven technical

"The revised timing reflects the event-driven nature of the study"

Event-driven describes an investment approach or market behavior that centers on specific, usually time-bound occurrences—such as mergers, earnings reports, regulatory decisions, product approvals, or restructurings—that can cause a company’s stock to move sharply. It matters to investors because these identifiable moments often create predictable price changes or risks, so traders position themselves ahead of or react quickly to the event much like a spectator placing a bet before a big game or booking a ticket for a movie release expected to draw a crowd.

At-The-Market program financial

"under the At-The-Market program remains at $75 million"

An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did IPHA report for the first nine months of 2026?

Innate Pharma reported revenue of €3.4 million for the first nine months of 2026, compared with €2.3 million for the same period of 2025. Revenue from collaboration and licensing agreements mainly reflects recognition of proceeds under agreements with AstraZeneca and Sanofi.

How much cash and financial assets did IPHA report?

Innate Pharma reported €96.8 million in cash, cash equivalents and financial assets as of September 30, 2026. The amount included the $75 million upfront payment from the Sobi transaction and aggregate gross proceeds from the €30 million private placement of ordinary shares in August 2026.

What is the remaining ATM balance for IPHA?

The balance available under Innate Pharma’s April 2023 sales agreement under the At-The-Market program was $75 million as of September 30, 2026.

Which patient groups are included in IPHA’s TELLOMAK-3 trial?

TELLOMAK-3 includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides. It is a Phase 3 study of lacutamab in cutaneous T-cell lymphoma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: November 5, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

INCORPORATION BY REFERENCE

This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quote from Jonathan Dickinson, Chief Executive Officer of the Company, on page 1, references to webcasts on the first and second page, the related Internet links, addresses, and attendance details, and the contact details on page six) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333-282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated November 5, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: November 5, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson

Title:    Chief Executive Officer

EXHIBIT 99.1

INNATE PHARMA REPORTS THIRD QUARTER 2026 BUSINESS AND FINANCIAL UPDATE

Marseille, France, November 5, 2026

•Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event

•Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027

•AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027

•Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028

•Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026.

“As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.”

1 Including short term investments (€20.6m) and non-current financial instruments (€6.0m).

Webcast and conference call will be held today at 2:00pm CET (8:00am ET)

Access to live webcast:

Click here

Participants may also join via telephone using the registration link below:

Click here

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com.

A replay of the webcast will be available on the Company website for 90 days following the event.

Pipeline highlights

IPH4502 (Nectin-4 exatecan ADC):

•IPH4502 is Innate Pharma’s proprietary Nectin-4-targeting ADC, combining a differentiated antibody, a proprietary stable linker and an exatecan payload, with the potential to overcome Enfortumab Vedotin (EV) resistance in urothelial carcinoma (UC) and target tumors with low or heterogeneous Nectin-4 expression beyond UC. IPH4502 is currently being evaluated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 (IPH4502-101; NCT06781983).

•As announced in July 2026 (Link PR), enrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types.

•Phase 1 dose-escalation data will be presented as a poster at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, on November 18, 2026 (Barcelona).

•Following the ENA presentation, Innate Pharma will host a hybrid event focused on IPH4502 on November 18, 2026, at 4:00 pm GMT (11:00 am ET) with in-person attendance in London at the IET London, Savoy Place and a live webcast accessible here.

Lacutamab (anti-KIR3DL2 antibody), developed in collaboration with Sobi:

•As announced on August 10, 2026 (Link PR), Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma.

•Following closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027.

•Phase 3 TELLOMAK-3 includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.

•Innate plans an FDA filing in H2 2027 for accelerated approval in Sézary syndrome based on the existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway (Link PR).

Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca:

•Enrollment is complete in the AstraZeneca-sponsored Phase 3 PACIFIC-9 study evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III NSCLC who have not progressed following platinum-based chemoradiation therapy.

•As announced on October 27 (Link PR), AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from

the second half of 2026 previously. The revised timing reflects the event-driven nature of the study.

Corporate update

•Frédéric Lombard, Chief Financial Officer, will step down from his position on December 31, 2026, to pursue new career opportunities. The Company thanks him for his contributions and dedication during his time with the Company. The Company has initiated a search of potential candidates to replace Mr. Lombard.

•As of September 30, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million.

Financial highlights for Q3 2026

Cash, cash equivalents and financial assets of the Company amounted to €96.8 million as of September 30, 2026, which includes the $75 million upfront payment resulting from the closing of the Sobi transaction and the aggregate gross proceeds from the €30 million private placement offering of ordinary shares that occurred in August 2026. Also as of September 30, 2026, financial liabilities amounted to €16.2 million.

Revenues for the first nine months of 2026 amounted to €3.4 million (€2.3 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly results from the partial or entire recognition of the proceeds received pursuant to the co-development and license agreements with AstraZeneca and research collaboration and license agreements with Sanofi.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen

VP, Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 31.2 KB